Lead Obesity Therapeutic
A compact non-GLP-1 peptide program built around validated metabolic biology
SofiaSante's lead obesity candidate is a non-GLP-1-based linear peptide therapeutic fewer than 40 amino acids long, designed around four obesity-relevant receptor systems selected from validated metabolic biology. Target identities are withheld for competitive and IP reasons.
The therapeutic concept is based on a multi-pathway metabolic design. Rather than relying on a single incretin mechanism, the candidate is intended to combine metabolic signalling with modulation of a non-incretin neuro-metabolic pathway implicated in appetite regulation, adiposity, glucose handling, insulin sensitivity, and fat-tissue inflammatory signalling.
The selected receptor systems are supported by preclinical research linking them to obesity biology, including body-weight regulation, appetite control, adipose tissue function, glucose handling, insulin sensitivity, energy balance, or metabolic inflammation. The proprietary candidate remains subject to synthesis and wet-lab validation.
Competitive efficacy ambition
Designed with the aim of delivering meaningful weight loss through a differentiated non-GLP-1 approach.
Improved tolerability
Aiming to improve treatment usability by reducing tolerability barriers that can limit dose escalation, adherence, and persistence.
Durability & performance
Longer duration of action, suitability for half-life extension, and improved long-term treatment performance.
Modular platform strategy
The lead candidate is being designed as a modular obesity platform that may be developed as a standalone therapy or studied in co-administration with established incretin therapies. This strategy is intended to preserve development optionality across obesity and related metabolic conditions, including type 2 diabetes, non-alcoholic fatty liver disease, now often referred to as metabolic dysfunction-associated steatotic liver disease, and Prader-Willi syndrome, subject to preclinical and clinical validation.